pharmaphorum| News & views on pharma and biotech’s evolving future

R&D

Sponsored

The UK life sciences sector at a crossroads: Bold decisions ...

We all want the same thing: for the UK to succeed, for our workforces to thrive, and for patients and the NHS to benefit.

Oncology

pharmaphorum podcast Episode 264, ITM's Dr Andrew Cavey

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Market Access

Can direct-to-employer models close the GLP-1 obesity care g...

Patients

Patient centricity beyond buzzwords: What works

There is a strong emphasis on patient centricity, but, in many cases, patient engagement is just used to validate pre-existing assumptions.

News

uniQure sets course to US filing for Huntington gene therapy

Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.

Featured Content

Patients

Patient centricity beyond buzzwords: What works

There is a strong emphasis on patient centricity, but, in many cases, patient engagement is just used to validate pre-existing assumptions.

Spotlight on

ASCO 2026

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Oncology

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

uniQure sets course to US filing for Huntington gene therapy

Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.

News

Jazz orchestrates a $4bn cancer alliance with AbCellera

Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.

News

MSD steps out with Protillion in $510m+ AI shindig

MSD has teamed up with Protillion Bio in a deal worth more than $510m, focusing on using the AI start-up's lab-in-the-loop platform for drug discovery

News

Moderna builds commercial muscle as new launches loom

Moderna expands its commercial team, as the FDA issues a mostly positive briefing document on its seasonal flu shot, due to face an adcomm tomorrow.

Views & Analysis

Patients

Patient centricity beyond buzzwords: What works

There is a strong emphasis on patient centricity, but, in many cases, patient engagement is just used to validate pre-existing assumptions.

Oncology

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

R&D

Sponsored

The UK life sciences sector at a crossroads: Bold decisions ...

We all want the same thing: for the UK to succeed, for our workforces to thrive, and for patients and the NHS to benefit.

Patients

Pharmacy sign with yellow townhouse in background

Community pharmacy is ready to lead. Now it needs the system...

Community pharmacy is the infrastructure that makes NHS long-term plans and ambitions possible. But infrastructure without investment does not hold.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Oncology

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.